Strike Pharma key facts
- Developer of individual-based cancer treatment designed to provide scalable personalized immunotherapy.
- It has raised $6.1M; the latest was Accelerator/Incubator in Apr 2025.
- Notable investors include Almi Invest, Nordic Mentor Network For Entrepreneurship, Eir Ventures, Flerie, Monesi Forvaltnings — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch Strike Pharma: the Monday email on marks, rounds and moves
Strike Pharma funding rounds
No funding rounds for Strike Pharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Strike Pharma investors
9 investors are on record for Strike Pharma, including Almi Invest, Nordic Mentor Network For Entrepreneurship, Eir Ventures and Flerie.
About Strike Pharma
Developer of individual-based cancer treatment designed to provide scalable personalized immunotherapy. The company uses an antibody-based method based on the genetic profile of each patient's tumor that attacks the tumor cells and leaves other normal cells in the body alone, enabling patients to get an affordable and effective treatment while reducing the risk of side effects.
- Sector
- Healthcare
- HQ
- Lund, Sweden
- Founded
- 2020
- Employees
- 10
- Website
- strikepharma.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Strike Pharma doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.